Lumida
/AVTX
⌘K
AVTX

AVTX

AVTX
$16.12USD-6.17%-1.06 today

MARKET CAP

864.5M

P/E (TTM)

FWD P/E

DAY RANGE

$16 – $18

52W RANGE

$10
$24

AI Summary

Stalk
StalkMedium

AVTX remains in a long-term uptrend but is currently consolidating in a tight range around the 9/20/50-day moving averages with flattening EMAs and neutral momentum. Medium-term bias stays bullish given Stage 2 structure above the rising 200-day SMA, yet short-term timing is unfavorable. Execution is best deferred until pullbacks into support zones (such as the 50-day SMA or the $18.75–$19.50 range) show clear absorption.

  • 15.9% average yield on loan portfolio tops BDC peers.
  • $1.7B investment pipeline indicates strong deal origination ahead.
  • Profitability remains weak; Q3 NII of $0.32 below $0.33 distribution.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Horizon Technology Finance Corporation (NASDAQ: HRZN) is a prominent player in the venture financing sector, specializing in providing debt capital to growth-oriented companies within the technology and life sciences industries. The firm utilizes a venture lending strategy that focuses on high-quality investments to optimize returns while seeking to capitalize on the increasing venture capital availability. Horizon aims to support innovative entrepreneurs seeking funds to expand their technologies, positioning itself well to benefit from a recovering macroeconomic landscape.

Bull says

  • 15.9% average yield on loan portfolio tops BDC peers.
  • $1.7B investment pipeline indicates strong deal origination ahead.
  • Q3 net investment income at $0.32/sh supports distributions.
  • Available liquidity of $125M plus $150M excess cash on hand.
  • Rising institutional ownership signals improving investor confidence.
  • Management forecasts venture ecosystem recovery to boost originations.

Bear says

  • Profitability remains weak; Q3 NII of $0.32 below $0.33 distribution.
  • NAV declined to $9.06/sh after fair-value adjustments.
  • High leverage exposes margins to rising interest costs.
  • Exit scarcity limits capital returns amid IPO/M&A drought.
  • Low earnings yield and downward revisions signal value trap.
  • Challenging exit market may delay portfolio monetization.

Investment themes with AVTX

Biotech +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 09-11-2026neutral

Transcript signals

Bull points

  • We believe 2024 valuations will begin to become more attractive because of six quarters of declining values.
  • We believe industries such as energy, technology, and healthcare are best positioned to resume M&A activity given their historically high earning results, public stock prices posting strong gains, and the elevated level of cash and liquidity on the balance sheets of technology, big pharma, and energy companies.
  • As market conditions improve over time, we continue to believe Verizon's solid reputation and long-term market presence will allow it to prudently accelerate its portfolio growth.

Bear points

  • VC investment activity levels remained depressed in Q4 as venture capital investments from 2021 and the first half of 2022 continued to face devaluation issues and stress liquidity levels during 2023.
  • VC-backed exit activity hit a decade low in 2023, as a modest market rally in the fourth quarter was not enough to fully open up the IPO market.
  • The M&A market for venture-backed companies remained at historic lows as a combination of unrealistic valuations and higher interest rates, combined with regulatory scrutiny, continued to keep acquirers on the sidelines.
Read full transcript analysis ›